Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies. The data are from a small study and a short time frame, but Structure was able to leverage the encouraging preliminary results into a private placement of securities.
It makes sense that when care navigation prioritizes the patient and better links them to care by reducing barriers and smoothing out the road to seeing a provider, the patient experiences better outcomes. Better outcomes also translates to fewer hospital readmissions, saving money for both patients and their employers.
Evvy's $14 million funding round was led by Left Lane Capital and included participation from General Catalyst, LabCorp Venture Fund, RH Capital, Ingeborg Investments, G9 Ventures, Virtue and Amboy Street Ventures. In total, Evvy has raised $19 million.
Transcarent announced a new provider network, which seeks to help its employer customers provide their staff with access to high-quality, affordable care. The network includes 10 health systems including Mount Sinai, Mass General Brigham and Intermountain Health.
As a combined entity, Virgin Pulse and HealthComp will serve more than 1,000 self-insured employers and more than 20 million members. New Mountain Capital will be the majority owner.